AstraZeneca’s Zavicefta meets primary endpoint in Phase III pneumonia trials
July 21, 2016Research and Development Antibiotics, AstraZeneca, zavifecta
AstraZeneca has announced results from a Phase III trial for its recently approved antibiotic, Zavicefta (ceftazidime-avibactam), which met its primary …
Galenica announces $1.53 billion Replysa acquisition
July 21, 2016Research and Development, Sales and Marketing Relypsa, Vifor pharma, galenica
Galenica has announced that it has entered into an agreement to acquire Relypsa in a deal worth $1.53 billion, which …
Roche beats forecasts in strong H1 results
July 21, 2016Research and Development, Sales and Marketing 2016, Q2, Roche, h1, results
Roche has published very encouraging full results for the first half of this year, with cancer drug sales helping to …
Zafgen ends lead drug development, shares plummet
July 21, 2016Research and Development zafgen
Zafgen has announced that it has dropped development of its lead drug candidate, beloranib, in order to focus on a …
New Irish pharma deal to save €750 million, says minister
July 20, 2016Sales and Marketing Ireland, Irish Pharmaceutical Healthcare Association
The Irish government has struck a deal with pharmaceutical manufacturers regarding the price and supply of medicines, which is expected …
NICE recommends PTC Therapeutics Duchenne muscular dystrophy treatment
July 20, 2016Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, PTC Therapeutics
PTC Therapeutics has announced that the National Institute for Health and Care Excellence has issued final guidance recommending Translarna (ataluren) …
AstraZeneca loses legal bid to block Crestor generics
July 20, 2016Research and Development, Sales and Marketing AstraZeneca, Crestor, FDA, generics, legal
A US district court judge has refused AstraZeneca’s request for a temporary restraining order blocking the approval of generic versions …
J&J boosted by pharma revenue in Q2 results
July 20, 2016Research and Development 2016, Johnson and Johnson, Q2, results
Shares at Johnson and Johnson have reached a record high of over $125 after pharma revenues helped to raise full …
Bristol-Myers Squibb settle $30 million California kickback lawsuit
July 20, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, california, lawsuit
Bristol-Myers Squibb (BMS) has agreed to pay $30 million to the California Department of Insurance to settle an almost decade …
FDA panel unanimously recommends approval of Valeant’s brodalumab with conditions
July 20, 2016Research and Development, Sales and Marketing FDA, Valeant, brodalumab
Valeant has announced that the US Food and Drug Administration’s (FDA) dermatologic and ophthalmic drugs advisory committee has recommended brodalumab …
Celgene boosts cancer portfolio with deal worth up to $2.5 billion with Jounce Therapeutics
July 19, 2016Research and Development, Sales and Marketing Celgene, jounce
Celgene has entered into a collaboration with Jounce Therapeutics that will see the pair jointly develop and commercialise Jounce’s lead …
Teva sells $15 billion in bonds to fund Allergan generics deal
July 19, 2016Manufacturing and Production, Sales and Marketing Allergan, Teva, bonds, generics
Teva Pharmaceuticals has announced that it has successfully finalised a bond sale totalling $15 billion that will help to fund …
Opdivo to go before EU, US regulators in head and neck cancer
July 19, 2016Manufacturing and Production, Research and Development EMA, EU, FDA, US, head and neck cancer, opdivo
Bristol-Myers Squibb has announced that its lead oncology drug, Opdivo (nivolumab), is set to go before regulators in the US …
Novartis lowers core operating profit outlook in Q2 results
July 19, 2016Manufacturing and Production, Research and Development, Sales and Marketing 2016, Novartis, Q2, results
Novartis has warned that its profits may decline this year as it issued second quarter results, with generic competition for …
New data shows superior viral suppression for Triumeq in women with HIV
July 18, 2016Manufacturing and Production, Research and Development Triumeq, ViiV Healthcare
ViiV Healthcare has presented late-stage data showing superior efficacy for combination treatment Triumeq (dolutegravir/abacavir/lamivudine) compared with atazanavir, plus other treatments, …
AstraZeneca presents positive Phase III results for lung cancer drug Tagrisso
July 18, 2016Manufacturing and Production, Research and Development AstraZeneca, Tagrisso
AstraZeneca has presented results from the latest Phase III trial evaluating Tagrisso (osimertinib) as a second line treatment for patients …
Roche’s lymphoma drug fails to beat rivals in Phase III trial
July 18, 2016Research and Development, Sales and Marketing Roche, lymphoma, phase III
Roche has announced that a Phase III trial evaluating Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated diffuse large B-cell lymphoma …
Samsung Bioepis Humira biosimilar gets accepted for EMA review
July 18, 2016Research and Development, Sales and Marketing EMA, Humira, Samsung Bioepis, application
The European Medicines Agency (EMA) has accepted for review the marketing authorisation application from Samsung Bioepis for their biosimilar version …
FDA approves first extended depth of focus lenses for people with cataracts
July 18, 2016Research and Development, Sales and Marketing Abbott, FDA, cataracts
Abbott has announced that the Tecnis Symfony Intraocular Lenses for the treatment of cataracts has been approved by the US …
Valeant’s psoriasis drug “difficult to assess”, according to FDA staff
July 18, 2016Research and Development, Sales and Marketing FDA, Valeant, psoriasis
Staff at the US Food and Drug Administration have expressed concerns over Valeant’s psoriasis candidate, brodalumab, due to the potential …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
